Citadel Advisors’s DICE Therapeutics, Inc. Common Stock DICE Stock Holding History

Citadel Advisors’s Portfolio DICE Stock Details DICE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-3,800	Closed	-$177K	–	15549
2023 Q2	$177K	Sell	3,800 -37,800	-91%	-$1.31M	﹤0.01%	10078
2023 Q1	$1.19M	Buy	41,600 +1,100	+3%	+$32.6K	﹤0.01%	6410
2022 Q4	$1.26M	Sell	40,500 -104,600	-72%	-$3.41M	﹤0.01%	6361
2022 Q3	$2.94M	Buy	+145,100	New	+$2.64M	﹤0.01%	4846

Citadel Advisors's DICE Position: Q3 2023 in Review

Citadel Advisors sold out of DICE Therapeutics, Inc. Common Stock (DICE) in Q3 2023, closing a stake of 869 shares — an estimated $40.4K sold.

Citadel Advisors first reported a position in DICE in Q4 2021 and held it in 7 quarters. The position peaked at $14.3M in Q2 2022. 0 funds tracked by Wall St. Rank hold DICE as of Q3 2023.

Citadel Advisors reported no remaining DICE Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
Citadel Advisors sold 869 DICE Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $40.4K.
Citadel Advisors first reported a position in DICE Therapeutics, Inc. Common Stock in Q4 2021 and held it in 7 quarters.
Citadel Advisors's DICE Therapeutics, Inc. Common Stock position peaked at $14.3M in Q2 2022.
0 funds tracked by Wall St. Rank held DICE Therapeutics, Inc. Common Stock as of Q3 2023.

Based on Citadel Advisors's 13F filing for Q3 2023, filed 14 Nov 2023.